This document provides a summary of Darlene C. Deecher's background and experience as a Director of Drug Discovery and Development. She has over 20 years of experience leading teams in target identification, drug discovery, preclinical and clinical development. Her expertise is in women's health, neuroscience, and endocrinology. She has directed projects from concept through regulatory approval and product launch. She has authored numerous publications and patent applications. Currently she is the Director of New Technology Access at the Juvenile Diabetes Research Foundation, overseeing the artificial pancreas project.

1. DARLENE C. DEECHER, Ph.D.
2570 Keiser Rd, Quakertown, PA 18951 ddeecher@comcast.net
215-529-7935 (H); 484-919-7253 (M) http://www.linkedin.com/pub/b/36/b77
Director Drug Discovery & Development
Leader/Collaborator/Strategist/Implementer
High-performing Pharmacologist/Neuroscientist/Endocrinologist with a proven record of directing and leading
teams to identify targets, discover new drugs and guide their clinical development. Expertise in leading drug
development processes from scientific concept to product launch including drug target identification, lead
optimization, preclinical model development, safety, regulatory interactions and submissions, biomarker
strategy, clinical, and business development and alliance activities. Extensive leadership and management
training with recognized abilities to set high standards, energize teams and utilize consensus-building skills to
achieve results under aggressive timelines.
 Pharmacology, Neuroscience, Endocrinology,  Regulatory Documentation, Labeling
Women’s Health Expertise, Diabetes Experience, Strategy
 Cross-Functional Collaborator  Team Leader & Effective Project Director
 Internal/External Verbal & Written Communicator  Skilled in Data Assessment & Reporting
 Strategic Planning & Change Implementation  Published Author & Inventor
CAREER ACHIEVEMENTS
Scientific expert in Women’s Health Research with specific focus in CNS-related dysfunction. Contributed
to content, procedures and training of drug discovery and development processes increasing efficiency and
productivity. Principal scientist on one compound completed through agency registrations, two compounds
to Phase I and advanced more than ten projects through various phases of drug discovery. Authored 30
technical research reports used in regulatory submissions published 60 peer-reviewed articles and inventor
on 12 patent applications. Mentored and developed scientists to excel in the areas of basic and applied
research.
EDUCATION
Temple University, Philadelphia, PA (Quality Assurance/Regulatory Affairs)-certificate
Ph.D., Syracuse University, Syracuse, NY (Toxicology/Pharmacology)
M.S., SUNY Albany, Albany, NY (Science Education)
B.S., Syracuse University, Utica, NY (Biology)
A.S., Mohawk Valley College, Utica, NY (Science)
PROFESSIONAL EXPERIENCE
Juvenile Diabetes Research Foundation International (JDRF), Washington, DC 2009
Director, New Technology Access, Government Relations
Project Director responsible for progress, decision-making, operational oversight within the artificial pancreas
project as part of the Diabetes Research Program. Responsibilities in this role include research, regulatory
strategy and agency interactions, government relations, alliance partnerships, major donor gift interactions,
clinician adoption and education as well as input on other areas of research within the JDRF organization.
• Preparation of strategic business plan for development plans of the artificial pancreas
WYETH PHARMACEUTICALS, Discovery, Collegeville, PA 1994-2008
Director, Women’s Health (2008)
Directed, coordinated, executed research in neuroendocrinology and menopausal health with specific focus on
CNS-related mechanisms. Responsible for operational and decision-making oversight as part of the senior
leadership team.
• Directed research in temperature regulation, sexual behavior, mood regulation and sleep

2. Page 2 DARLENE C. DEECHER, Ph.D. 215-536-8789
• Prepared INDs application for small molecules for CNS-related menopausal complaints
• Participated in strategic & budgetary planning
• Nominated to participate in “Women as Leaders” Executive-selected Program
• Constructed and presented 3-year business plan for menopausal health
• Evaluated multiple in-license opportunities with cross-therapeutic potential (Neuroscience)
• Published ten peer-reviewed scientific articles and presented at external scientific meetings
• Developed content for workshop on “Translation of Preclinical In Vivo Data”
• Evaluated scientific merit of projects for competitive fellowships, Ursinus College, Collegeville, PA
• Awarded external recognition “Woman of the Year for Scientific Contributions to Women’s Health”
• Completed asset exit document for business development and closure of research laboratories
Associate Director, Women’s Health (2004-2007)
Directed, coordinated, executed research in neuroendocrinology and menopausal health
• Managed 14 direct reports in biological research (temperature regulation, sexual behavior, mood
regulation and sleep).
• Led two discovery teams directing cross-disciplinary teams (biologist, chemists, safety & early clinical
scientists) and evaluated scientific content for business development
• Authored white paper on the scientific understanding of depression and the relationship to mood
disorders in Women for executive management & formally presented the scientific platform
• Participated in generating uniform templates for regulatory documentation (IND, IMPD, IB, NDA) and
prepared three INDs/IBs, four IMPDs, one NDA, one NDS, one MAA for drug applications
• Provided scientific content, regulatory strategy and labeling content for a Phase III clinical compound
• Co-leader of a cross functional group on a small molecule target for pain management
• Organized, coordinated & presented training course “Managing for Performance”
• Published thirteen peer reviewed scientific articles, evaluated postdoctoral research proposals for
selection committee and presented at external scientific meetings
• Completed 2-year comprehensive R & D leadership program (top 5% R & D performance “Eagles”)
• Established a successful collaboration with Dr. Blakely, Vanderbilt Univ., supporting one postdoctoral
student investigating monoamine transporter binding interactions
• Developed animal models in sexual behavior and mood for drug screening
Principal Scientist -III (2003), -II (2002), -I (2001) Endocrinology (2001-2003)
Conducted and led basic and applied research in neuroendocrinology, neuroscience and women’s health
• Contributed scientific content as part of a cross-disciplinary team for a Phase III compound being
developed for major depressive disorder and menopausal symptoms
• Managed 6-10 direct reports in biological research
• Prepared one investigational drug application and presented/discussed with regulatory agencies
• Co-led chemists, biologists & safety scientists (35 members) on two discovery projects
• Advanced one compound to development & one molecular target to exploratory phase
• Organized and moderated Academic Symposium “Female Sexual Dysfunction: preclinical & clinical”
• Developed content, gained Executive endorsement & implemented training for 200 senior chemists,
biologists & safety scientists on new drug discovery processes (presented content at all discovery sites)
• Published five scientific articles and presented at external scientific meetings
• Initiated research in causality of menopause-induced symptoms & developed animal models in
temperature regulation to support discovery efforts
Senior Scientist -III (2000), -II (1998-99), -I (1997) Molecular Biology (1997-2000)
Directed research to identify exploratory drug targets in neuroendocrine pathways
• Developed & implemented high throughput screening (HTS) format for G-protein receptor target

3. Page 3 DARLENE C. DEECHER, Ph.D. 215-536-8789
• Received Wyeth Recognition Award for execution excellence of new target screen & lead optimization
• Published ten scientific articles and presented at external scientific meetings
• Led exploratory research to identify new targets involved in estrogen action in central nervous system
Senior Scientist, Peptide Pharmacology (1994-1996)
Establish a pharmacology laboratory as part of the newly formed Women’s Health Research Institute. Planned
and performed research in receptor pharmacology in support of departmental goals.
• Established laboratory, including major equipment purchases, for receptor pharmacology group
• Developed in vitro assays to support G-protein coupled receptor (GPCR) targets for contraception
• Coordinated high throughput screening for primary in vitro assays
• Directed chemistry on small molecule contraceptive target (GPCRs)
• Provided technical receptor pharmacology support to cross-functional research teams
• Published two scientific articles and presented at external scientific meetings
ABBOTT LABORATORIES, New Lead Discovery, Abbott Park, IL 1992-1994
Senior Pharmacologists-Neuroscience related
Established laboratory and group responsible for identification of neuroscience targets, development and
implementation of all high throughput screens for small molecules and natural products.
• Established in vitro assay platforms for GPCRs, enzymes, ion channels and second messengers
• Coordinated screening efforts with Neuroscience project teams
• Directed biology efforts to identify novel compounds from natural products
• Published three peer-reviewed scientific articles and one book chapter on drug receptors
• Participated in animal use and care governing committee reviewing animal protocols
• Assessed new technologies and screening applications with recommendations for process change
• Company spokeswoman promoting science education
RESEARCH TRAINING
Albany Medical College, Pharmacology, Albany, NY 1990-1992
Postdoctorate Training: Pharmacological characterization of novel opiate and serotoninergic compounds
Published three peer-reviewed scientific articles. Mentors S. Glick/M. Teitler
NYSAES, Cornell University, Geneva, NY 1989-1990
Postdoctorate Training: Molecular interactions of neurotoxic agents on voltage-dependent sodium channels in
the mammalian central nervous system. Published four peer-reviewed scientific articles. Mentor D. Soderlund
PROFESSIONAL DEVELOPMENT
Leadership training for Future Women Leaders in R & D (2007-2008)
Eagles Leadership training program (2004-2006)
Drug Development 5-day Training (2005)
Women Leadership Training for Drug Discovery Research (2005)
Drug Development Lecture Series (2002, 15 hours classroom instruction)
Structure & Function G-Protein receptors: New Opportunities for Commercial Dev., Philadelphia, PA (2002)
Leading Work Teams Workshop (2001, 2-days)
Presentation skills and tour guide training for external communications (1995, 2-days)

4. Page 4 DARLENE C. DEECHER, Ph.D. 215-536-8789
PROFESSIONAL ADDENDUM
INVITED PEER REVIEWS/BOOK CHAPTERS
DC Deecher (2009) The Pathophysiology of the Thermoregulatory Dysfunction Underlying Menopausal Hot
Flashes. Frontiers in Bioscience Current Issues in Thermal Physiology. American Physiological Society's
"Handbook of Physiology. Ed. Clark Blatteis.
DC Deecher (2008) Thermoregulation and Menopause: Understanding the Basic Pathophysiology of
Vasomotor Symptoms. In Menopausal Transition: The Interface Between Psychiatry and Gynecology. Eds
C. Soares & M. Warren S. Krager AG Basel Switzerland.
DC Deecher (2007) Understanding the Pathophysiology of Vasomotor Symptoms (Hot Flushes and Night
Sweats) That Occur in Perimenopause, Menopause and Postmenopause Life Stages. Archives of Women’s
Mental Health 10(6) 247-257.
DC Deecher, T Andree, D Sloan & L Schechter (2008) From menarache to menopause: Exploring the
underlying biology of depression in women experiencing hormonal change. Psychoneuroendocrinology,
33:3-17.
DC Deecher (2005) Physiology of thermoregulatory dysfunction and current approaches of treatment for
vasomotor symptoms. Expert Opinion on Investigational Drugs V14 (4) 1-14.
SE Counts, SE Perez, U. Kahl, T. Bartfai, R. Bowser, DC Deecher, DC Mash, JN Crawley & EJ Mufson
(2001) Neurobiology of galanin: mechanisms and therapeutic potential for Alzheimer’s Disease. CNS
Drug Reviews Vol 7(4): 445-470.
M. Williams, DC Deecher & J. P. Sullivan (1993) Drug Receptors (Chapter 11). Burger’s Medicinal
Chemistry and Drug Discovery. (Ed. M. E. Wolff) Wiley-Interscience, 5th Edition.
RESEARCH PUBLICATIONS (refereed)
DC Deecher, X. Chen, J Roman, S Cosmi (2009). Evaluation of Age and Ovariectomy time on Temperature
dysregulation in the Ovariectomized Rat. Endocrinology in preparation.
DC Deecher, S Cosmi, L Leventhal, R Winneker (2009). Norepinephrine reuptake inhibition alleviated
temperature dysregulation in the Ovariectomized Rat. Endocrinology in preparation.
DC Deecher, S Cosmi, E Koury, P Alfinito, R Winneker (2009) Evaluation of norepinephrine reuptake
inhibition and serotonin receptor2A interaction in temperature regulation in the Ovariectomized Rat.
Neuroendocrinology in preparation.
EJ Koury, PD Alfinito, P. Zhang, C. Stephens, J, Yao, D. Yates and DC Deecher (2009). Comparative
evaluation of reboxetine's pharmacokinetic properties with biomarker endpoints in female cynamologous
monkeys. Brain Research in preparation
KD Dave, JA Bray, DC Deecher (2009) Administration of 17β-estradiol to ovariectomized mice reduces
anxiety in the marble burying model. Hormones & Behavior in preparation.
DC Deecher, R. Mastroeni C Maddage, P. Alfinito, A. Pawlyk (2009) Development of a Female Rat Model of
Sexual Low Motivation for Subchronic Dosing Administration. Animal Behavior in preparation
DC Deecher, C Maddage, X. Chen, S Cosmi, A Pawlyk, P. Alfinito. (2009) Development of a Female Rat
Model of Sexual Low Motivation. Hormones & Behavior in preparation.
DC Deecher, C Maddage, A. Pawlyk, K Dave, X. Chen, R. Mastroeni, S Cosmi, P. Alfinito. (2009) Oxytocin
improves sexual function in a Female Rat Model of Sexual Low Motivation. Neuropharm in preparation.
A Pawlyk, R. Mastroneni, PD Alfinito, S Cosmi, DC Deecher (2009) Imixolan Exerts Multiple Effects on
Temperature Regulation in Ovariectomized Rats. JPET in preparation.
GT Whiteside, JM Dwyer..DC Deecher et al., LLeventhal (2009) Elevation of norepinephrine, without
serotonin, is sufficient for analgesic and anti-depressant activity. JPET in review.
PD Alfinito, X Chen, R Mastroeni, AC Pawlyk & DC Deecher (2009) Estradiol increases catecholamine levels
in the hypothalamus of ovariectomized rats during the dark-phase. European J Pharm 616(1-3): 334-339.
GD Heffernan, RD Coghlan, ES Manas, RE McDevitt, Y Li, PE. Mahaney, AJ Robichaud, EJ Trybulski, PD
Alfinito, JA Bray, SA Cosmi, GH Johnston, T Kenney, E Koury & DC Deecher (2009) Dual acting

5. Page 5 DARLENE C. DEECHER, Ph.D. 215-536-8789
norepinephrine reuptake inhibitors and 5-HT2A receptor antagonists: Identification, synthesis and activity of
novel 4-dialkylaminoethyl-3-(phenylsulfonyl)-1H-indoles. Bioorganic & Medicinal Chemistry in press
AT Vu, ST Cohn, EA Terefenko, WJ Moore, P. Zhang, PE Mahaney, EJ Trybulski, R Dooley, JA Bray, GH
Johnston, J Leiter & DC Deecher (2009) 3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual
norepinephrine and serotonin reuptake inhibitors. Bioorg & Med Chem Letters, 19(9):2464-2467.
CY Kim, PE Mahaney, O McConnell, Y Zhang, E Manas, DM Ho, DC Deecher, EJ Trybulski (2009) Discovery
of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.
Bioorg & Med Chem Letters 19:5029-5032.
PE Mahaney, CY Kim, RD Coghlan, ST Cohn, GD Heffernan, CA Huselton, EA Terefenko, AT Vu, P Zhang,
KD Burroughs, SA Cosmi, JA Bray, GH Johnston, DC Deecher, EJ Trybulski (2009) Structure-activity
relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake
inhibitors. Bioorg & Med Chem Letters 19(19): 5807-5810.
S Cosmi, A Pawlyk, PD Alfinito, J Roman, DC Deecher (2009) Telemetric Measurement Of Tail-Skin and
Core Body Temperature in Ovariectomized Rat. J NeuroSci Methods 178(2):270-275.
EJ Koury, AC Pawlyk, CL Smolenski, TJ Berrodin, S Nagpal & DC Deecher (2009) Characterization of
Ligands for Thyroid Receptor Subtypes and their Interactions with Co-Regulators. Steroids 74(2):270-276.
P Zhang, EA Terefenko, C McComas, P Mahaney, A Vu, E Trybulski, E Koury, G Johnston, J Bray, DC
Deecher (2008) Synthesis and Activity of Novel 1- or 3-(3-Amino-1-phenyl propyl)-1,3-dihydro-2H-
benzimidazol-2-ones as Selective Norepinephrine Reuptake Inhibitors. Bioorganic Med Chem Letters
18:6067-6070.
PD Alfinito, X Chen, J Atherton, S Cosmi, DC Deecher (2008) ICI 182,780 Penetrates Brain and
Hypothalamus Tissue and has Antiestrogenic and Estrogenic Actions in the Brain Following Systemic
Dosing. Endocrinology 149 (10):5219-5226.
AC Pawlyk, PD Alfinito, DC Deecher (2008) Effect of 17α-Ethinyl Estradiol on Active Phase Rapid Eye
Movement Sleep Microarchitecture. European J Pharm 591(1-3):315-8.
CC McComas, A Vu, PE Mahaney, S Cohn, A Fensome, MA Marella, L Nogle, EJ Trybulski, F Ye, P Zhang, P
Alfinito, J Bray, G Johnston, E Koury, DC Deecher (2008) Synthesis and activity of 1-(3-amino-1-
phenylpropyl)indolin-2-ones: A new class of selective norepinephrine reuptake inhibitors Synthesis and
activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: A new class of selective norepinephrine reuptake
inhibitors. Bioorganic Med Chem Letters 18(18):4929-31.
P Mahaney, LK Gavrin, EJ Trybulski, AT. Vu, GP Stack, S Cohn, JP Sabatucci, F Ye,J Belardi, A Santilli, J
Leiter, GH Johnston, JA Bray,† K Burroughs, S Cosmi, L Leventhal,† E Koury, Y Zhang, C Mugford, DM
Ho, S Rosenzweig-Lipson, B Platt & DC Deecher (2008) SAR of the Cycloalkanol Ethylamine Scaffold:
Discovery of Selective Norepinephrine Reuptake Inhibitors –J Med Chem 51(13):4038-49
A Pawlyk, P Alfinito, G Johnston & DC Deecher (2008) Subchronic 17α-ethinyl estradiol differentially
affects subtypes of sleep and wakefulness in ovariectomized rats. Hormones & Behavior 53:217-224.
JH. Mason, DC Deecher, RJ Richmond, G Stack, PE Mahaney, EJ Trybulski, RC Winneker & RD. Blakely
(2007) Desvenlafaxine succinate (DVS) identifies novel antagonist binding determinants in the human
norepinephrine transporter. J Pharm Exp Therap: 323:1-10.
DC Deecher, P Alfinito, L Leventhal, GH. Johnston, S Cosmi, I Merchenthaler* & R Winneker (2007)
Alleviation of thermoregulatory dysfunction with the new serotonin and norepinephrine reuptake inhibitor
desvenlafaxine succinate in ovariectomized rodent models. Endocrinology 148(3) 1376-1383.
N Maswood, PD. Alfinito, S Cosmi, L Leventhal, GH Johnston & DC Deecher (2006) Evaluation of the
Selective Serotonin Reuptake Inhibitor, Fluoxetine, in Ovariectomized (OVX) Rat Models of Temperature
Regulation. Neuroendocrinology 85(5):330-338.
AC Pawlyk, S Cosmi, PD Alfinito, DC Deecher (2006) Mirtazapine Exerts Multiple Effects on Temperature
Regulation in Ovariectomized Rats. Brain Research 1123 (1): 135-144.
DC Deecher, CE Beyer, G Johnston, J Bray, S. Shah, M. Abou-Gharbia and TH Andree (2006)
Desvenlafaxine Succinate: A New Serotonin and Norepinephrine Reuptake Inhibitor. J Pharm Exp
Therapeutics 318:657-665.
PD Alfinito, C Huselton, X Chen and DC Deecher (2006) Pharmacokinetic and pharmacodynamic profiles of

6. Page 6 DARLENE C. DEECHER, Ph.D. 215-536-8789
the novel serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized
Sprague-Dawley rats Brain Research 1098:71-78.
DC Deecher. 2005. Physiology of thermoregulatory dysfunction and current approaches of treatment for
vasomotor symptoms. Expert Opinion on Investigational Drugs V14 (4) 1-14.
L Leventhal, S Cosmi & DC Deecher (2005) Effect of Calcium Channel Modulators on Temperature
Regulation in Ovariectomized Rats. Pharm Biochem Behav 80 (3) 511-520.
DC Deecher, P Daoud, R Bhat and LT O’Connor (2005). Endogenously expressed estrogen receptors mediate
neuroprotection in a hippocampal cell line (HT22). J Cell Biochem 95 (2): 302-312.
PE Stevis and DC Deecher. (2005) Analysis of glycoprotein hormone receptor extracellular domain
interactions using a solid-phase capture assay. Analytical Biochemistry 338 (2): 320-325.
K Sipe, L Leventhal, K Burroughs, S Cosmi, GH Johnston & DC Deecher (2004) Serotonin 2A Receptor
Modulates Tail-Skin Temperature in Two Rodent Models of Thermoregulatory Dysfunction. Brain
Research 1028: 191-202.
PE Stevis, BJ Arey, DC Deecher (2004) A Glutathione-S-Transferase-FSHα subunit hybrid associates with
FSHα, retains biological activity and facilitates purification. BBRC 319:1025-1030.
DC Deecher, P Swiggard, DE Frail & LT O’Connor (2003) Characterization of a membrane estrogen receptor
in a rat hypothalamic cell line (D12) Endocrine 22(3) 211-224.
B.J. Arey, DC Deecher, ES Shen, PE Stevis, J Wrobel, DE Frail & FJ López (2002) Identification and
characterization of a selective, non-peptide follicle-stimulating hormone receptor antagonist.
Endocrinology 143(10) 3822-3829.
J Wrobel, D Green, J Jetter, W Kao, J Rogers, M. Claudia Perez, J Hardenburg, DC Deecher, FJ Lopez, BJ
Arey and ES Shen (2002) Synthesis of (bis)Sulfonic Acid, (bis)Benzamides as Follicle-Stimulating
Hormone (FSH) Antagonists. Bioorganic Med. Chem.10: 639-656.
DC Deecher and FJ López (2002) Discrimination of galanin receptor subtypes in RINm5F cells by structurally
different galanin radioligands. Peptides 23: 545-553.
EJ Mufson, DC Deecher, M. Basile, S. Izenwasser and DC Mash. (2000) Galanin receptor plasticity within the
Nucleus Basalis in early Alzheimer’s disease: an in vitro autoradiographic analysis. Neuropharmacology
39(8):1404-1412.
PE Stevis, DC Deecher, L. Suhadolnik, LM Mallis and DE Frail (1999) Differential Effects of Estradiol and
Estradiol-BSA Conjugates. Endocrinology (Rapid Communication) 140(11) 5455-5458.
SL Fitzpatrick, TJ Berrodin, SF Jenkins, DM Sindoni, DC Deecher, DE Frail. (1999) Effect of estrogen
agonist and antagonists on induction of progesterone receptor in a rat hypothalamic cell line.
Endocrinology 140(9) 3928-3937.
PE Stevis, DC Deecher, FJ López and DE Frail (1999) Expression and Pharmacological Characterization of
the Soluble Human FSH receptor Extracellular Domain: Facilitated Secretion by FSH. Endocrine 10(2)
153-160.
SL Fitzpatrick, JM Funkhouser, DM Sindoni, PE Stevis, DC Deecher, AR Bapat, I. Merchanthaler, DE Frail.
(1999) Expression of Estrogen Receptor-β Protein in Rodent Ovary. Endocrinology 140(6)2581-2591.
E. J. Mufson, A. Ulrika Kahl, Jeffrey H. Kordower, Robert Bowser, Deborah C. Mash and DC Deecher
(1998). Galanin Expression within the Basal Forebrain In Alzheimer’s Disease: Comments On Therapeutic
Potential. Annals of the New York Academy of Science 863:291-304.
GT Payne, DC Deecher and DM Soderlund (1998) Structure-activity relationships for the action of
dihydropyrazole insecticides on mouse brain sodium channels. Pesti. Biochem. Physiol. 60:177-185.
ES Shen, EH Meade, MC Pérez, DC Deecher, A. Negro-Vilar and FJ López (1998) Expression of functional
estrogen receptors and galanin mRNA in immortalized luteinizing hormone-releasing hormone neurons:
Estrogenic control of galanin gene expression. Endocrinol. 139 (3) 939-948.
DC Deecher, D. C. Mash, J. K. Staley and E. J. Mufson (1998) Characterization and localization of galanin
receptors in human entorhinal cortex. Regulatory Peptides 73:149-159.

7. Page 7 DARLENE C. DEECHER, Ph.D. 215-536-8789
B.J Arey, PE Stevis, DC Deecher, ES Shen, D Frail and FJ López (1997) Induction of promiscuous G-protein
coupling of the FSH receptor: A novel mechanism for transducing pleiotropic actions of FSH isoforms.
Mol. Endocrinol 11(5): 517-526.
A.G Schultz, A. Wang, C. Alva, A. Sebastian, S. D. Glick, DC Deecher and J. M. Bidlack (1996) Asymmetric
syntheses, opioid receptor affinities and antinociceptive effects of 8-amino-5, 9methanobenzocyclooctenes,
a new class of structural analogues of the morphine alkaloids. J. Med. Chem. 39:1956-1966.
DC Deecher, O. Odusan & E. Mufson (1995) Galanin receptors in Human Basal Forebrain Differ from
receptors in the hypothalamus: Characterization using [125I] galanin (porcine) and [125I] galantide. J.
Pharmacol. Exp. Ther. 275:720-727.
DC Deecher, B. D. Wilcox, P. Conley & H. Kimelberg (1993) Detection of 5HT2 receptors and 5HT-uptake
sites using radioligand binding, northern blot analysis and Ca2+ in rat primary astrocyte cultures. J.
Neuroscience 35: 246-256.
A. Sebastian, J. M. Bidlack, Qi Jiang, DC Deecher, M. Teitler, S. D. Glick & S. Archer (1993) 14b-[(p-
Nitrocinnamoyl)amino]morphinones, 14b-[(p-Nitrocinnamoyl)amino]-7,8-dihydromorphinones and their
codeinone analogues: Synthesis and receptor activity. J. Med. Chem. 36: 3154-3160.
DC Deecher, M. Teitler & S. D. Glick (1992) Mechanisms of action Ibogaine and Harmaline based on
radiolabeled ligand binding sites. Brain Research 571: 242-247.
DC Deecher. & D. M Soderlund (1991) RH 3421, An insecticidal pyrazoline, inhibits sodium channel-
dependent sodium uptake in mouse brain preparations. Pesti. Biochem. & Physio. 39:130-137.
DC Deecher & D. M Soderlund (1991) Inhibition of sodium channels and [3H]Batrachotoxin A-20-benzoate
binding by a dihyropyrazole neurotoxin. Pesti. Biochem. & Physio. 41: 265-273.
DC Deecher, Payne, G. & D. M. Soderlund (1991) Mode of action of dihydropyrazoles on sodium channels,
in Extended Summaries Neurotox '91-An International Symposium on the Molecular Basis of Drug and
Pesticide Action. Pesti. Sci. 33: 128-129.
DC Deecher, J. Brezner & S. W. Tanenbaum (1990) Sublethal effects of Avermectin B1a and Milbemycin D
on gypsy moth (Lepidoptera: Lymantriidae) larvae. J. Econ. Entomol. 83(3): 710-714.
DC Deecher, J. Brezner & S. W. Tanenbaum (1990) Effects of 4"-epi-methylamino-4"-deoxyavermectin B1
hydrochloride (MK-243) on gypsy moth (Lepidoptera: Lymantriidae) larvae. J. Econ. Entomol. 83(3):
917-919.
DC Deecher, J. Brezner & S. W. Tanenbaum (1989) Effects of abamectin and milbemycin D on the gypsy
moth (Lepidoptera: Lymantriidae). J. Econ. Entomol. 82: 1395-1398.
DC Deecher, J. Brezner & S. W. Tanenbaum (1987) Avermectin B1a and milbemycin D as contact toxicants
for gypsy moth (Lepidoptera: Lymantriidae) larvae and eggs. J. Econ. Entomol. 80: 1284-1287.
ABSTRACTS SCIENTIFIC MEETINGS (2006-2008; 1989-2005 supplemental)
DC Deecher, C Maddage, X Chen, T Zhou, S Cosmi, AC Pawlyk, PD Alfinito, KD Dave, R Winneker. 2009
Development of a Female Rat Model of Low Sexual Motivation and Receptivity. Neuroscience, Oct 09,
Chicago, IL
KD Dave, AC Pawlyk, C Maddage, PD Alfinito, R Mastroeni, J Roman, X Chen, S Cosmi, DC Deecher. 2009
Oxytocin stimulates female sexual behaviors in ovariectomized Long-Evans rats. Neuroscience, Oct 09,
Chicago, IL
S Cosmi, Pawlyk, PD Alfinito, J Roman, DC Deecher. 2008 Telemetric monitoring of tail-skin and core body
temperature in ovariectomized rats. Society Neuroscience, Nov 08, Washington DC
KD Dave, JA Bray, DC Deecher 2008 Administration of 17β-estradiol to ovariectomized mice reduces
anxiety in the marble burying model. Society Neuroscience, Nov 08, Washington DC
DC Deecher, C Maddage, J Bray, S Cosmi, A Pawlyk, P. Alfinito. 2008 Evaluation of partner preference in a
3-chamber test box using hormone-primed ovariectomized long evans rats. Int’l Behav Neurosci St.
Thomas, June 17-22, 2008

8. Page 8 DARLENE C. DEECHER, Ph.D. 215-536-8789
P.D. Alfinito, X. Chen, J. Atherton, X. Ma, DC Deecher 2008. Penetration of the Antiestrogen ICI 182,780
into Brain and Hypothalamus Tissues of Ovariectomized Sprague-Dawley Rats. Endocrine Society, June
2008 San Francisco, CA
DC Deecher, JN Mason, RJ Richmond, G Stack, PE Mahaney, E Trybulski, RC Winneker, RD Blakely. 2007
Desvenlafaxine succinate (DVS) identifies novel antagonist binding determinants in the human
norepinephrine transporter Society of Neuroscience, Nov 07 San Diego, CA
PD Alfinito, AC Pawlyk, X Chen, C Stephens, DC Deecher 2007 Estradiol Benzoate Increases Catecholamine
Release in the Hypothalamus of Ovariectomized Rats During the Dark-phase. Neuroscience, Nov 07 San
Diego, CA
S Cosmi, C Maddage, J Bray, AC Pawlyk, PD Alfinito, DC Deecher 2007 Assessment of Partner-Preference
in a 3-Chamber Test Box Using Hormone-Primed Ovariectomized (OVX) Long Evans Rats Society of
Neuroscience, Nov 07 San Diego, CA
S Cosmi, C Maddage, J Bray, AC Pawlyk, P Alfinito & DC Deecher. 2007 Assessment of Partner-Preference
in a 3-Chamber Test Box Using Hormone-Primed Ovariectomized (OVX) Long Evans Rats. Society
Neuroscience, Nov 06, San Diego, CA
DC Deecher, JN Mason, RJ Richmond, G. Stack, PE Mahaney, E Trybulski, RC Winneker & RD Blakely
2007 Desvenlafaxine succinate (DVS) identifies novel antagonist binding determinants in the human
norepinephrine transporter. Society Neuroscience, Nov. 6, 2007, San Diego, CA
DC Deecher, PD Alfinito, L Leventhal, S Cosmi, CE Beyer, S Rosenzweig-Lipson, LE Schechter, M Abou-
Gharbia, RC Winneker &TH Andree. 2007 Preclinical Evaluation of Desvenlafaxine Succinate: A New
Serotonin and Norepinephrine Reuptake Inhibitor. Endocrine Society, June 2007 Toronto, CA
AC Pawlyk, G Johnston, PD Alfinito & DC Deecher. 2007 Subchronic Treatment With 17α-Ethinyl Estradiol
Suppresses Dark Phase REM Sleep In Ovariectomized Rats For Up To Six Days. Endocrine Society, June
2007 Toronto, CA
EJ Trybulski, PE Mahaney, LK Gavrin, AT Vu, S Cohn, D Jenkins, J Sabatucci, F Ye, MB. Webb, K Sipe, J
Leiter, G Johnston, K Burroughs, S Cosmi, L Leventhal, Y Zhang, C Mugford, S Rosenzweig-Lipson, B
Platt & DC. Deecher Discovery of Novel and Selective Norepinephrine Reuptake Inhibitors: A
Reinvestigation of the Cyclohexanol Ethylamine Scaffold. ACS, Sept 06, San Francisco, CA
N Maswood, J Bray, DC Deecher. Measurement of female sexual behavior in hormone-primed
ovariectomized rats by partner-prefernce and paced mating paradigms using a video track
system. Neuroscience, Oct 06, Atlanta, GA
AC Pawlyk, G Johnston, PD Alfinito, DC Deecher. The effects of repeated administration of 17a-ethinyl
estradiol on sleep in the ovariectomized rat. Neuroscience, Oct 06, Atlanta, GA
AC Pawlyk, S Cosmi, N Maswood, P Alfinito, DC Deecher. Effects of the 5HT2a antagonist mirtazapine in
models of thermoregulation. Neuroscience, Oct 06, Atlanta, GA
PD Alfinito, S Cosmi, X Chen, C Huselton & DC Deecher. Desvenlafaxine succinate (DVS), a new chemical
entity, specifically modulates temperature control in rodent models of thermoregulation. Neuroscience, Oct
06, Atlanta, GA
Navin Maswood , Scott Cosmi, Peter Alfinito, Liza Leventhal & DC Deecher. Evaluation of a selective
serotonin reuptake inhibitor, fluoxetine, on temperature regulation in ovariectomized rat models.
Neuroscience, Oct 06, Atlanta, GA
Deecher DC, Johnston G, Bray J, Sullivan K andree T and Abou-Gharbia M (2006) In Vitro Profiling of
the new serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate CINP July 06,
Chicago, IL
Deecher DC, Beyer CE, Alfinito P, Leventhal L, Cosmi S, Abou-Gharbia M and Winneker R
Restoring Temperature Regulation With The Serotonin And Norepinephrine Reuptake Inhibitor
Desvenlafaxine Succinate CINP July 06, Chicago, IL
Andree TH, Rosenzweig-Lipson S, Lin Q, Deecher DC, Ludwig B, Dawson LA, Schechter LE, Abou-Gharbia
M and Beyer CE (2006) Preclinical Evidence For Antidepressant & Anxiolytic Efficacy Of The New Dual
Serotonin And Norepinephrine Reuptake Inhibitor Desvenlafaxine Succinate CINP July 06, Chicago, IL

9. Page 9 DARLENE C. DEECHER, Ph.D. 215-536-8789
DC Deecher, P Alfinito, G Johnston, S Cosmi, L Leventhal, J Bray, R Winneker (2006) Desvenlafaxine
succinate, a new chemical entity, has potential as a nonhormonal therapy for treatment of vasomotor
symptoms. Endocrine Society, June 2006 Boston, MA
DC Deecher, L Leventhal, S Cosmi and N Maswood (2006) Acute effects of serotonin ligands in rat models of
ovariectomy-induced thermoregulatory dysfunction. Endocrine Society June 2006, Boston, MA
DC Deecher, Beyer CE, Alfinito P, Leventhal L, Cosmi S, Abou-Gharbia M and Winneker R (2006) Restoring
Temperature Regulation With The Serotonin And Norepinephrine Reuptake Inhibitor Desvenlafaxine
Succinate. Endocrine Society June 2006, Boston, MA
T Andree, DC Deecher, L Dawson, L Leventhal, K Rogers, P Mitchell, L Schechter, S Rosenzweig-Lipson, C
Beyer (2006) Desvenlafaxine: Preclinical Evidence for Serotonin and Norepinephrine Reuptake Inhibition,
Antidepressant and Antinociceptive Activity. APA, May 2006 Toronto
PATENT APPLICATIONS (Inventor)
Characterization of a membrane estrogen receptor, filed 6/2001; PCT filed 12/03
Methods of treating thermoregulatory disorders: modulation of norepinephrine (NE) levels in combination
with 5HT2a receptor antagonist, provisional filed 10/2002, final filed 10/14/03; WO2005/030750
Use of norepinephrine reuptake modulators for treating thermoregulatory disorders;
US2004-0152710A1& US2004-0143008A1
Agonism of the 5HT2a receptor for treatment of thermoregulatory dysfunction, provisional 9/02, final
9/03
Adrenergic alpha2B provisional filed 10/14/03 AM101498 foreign 1/05
Novel interaction of venlafaxine-like compounds at the norepinephrine transporter; AM101866
Combinations of NRI and SERM and methods of their use; AM101823
Triple monoamine transporter inhibitors for the treatment of vasomotor symptoms
PRESENTATIONS (invited)
Career Options for Scientists: Opportunities in Private and Nonprofit Sectors. Neurogenomics Postdoctoral
Training Program. Vanderbilt University, Nashville, TN Oct. 13, 2009.
Challenges of developing preclinical rodent models of sexual motivation for drug discovery purposes.
Symposium: Translational research on sexual function. Int’l Behav Neurosci St. Thomas, June 18, 2008.
Drug Discovery Research: “Molecule to Marketplace” Vanderbilt University, Nashville, TN Nov. 30, 2007.
Pathophysiology of Hot Flushes. Am Society of Reproductive Medicine, New Orleans, LA Oct 25, 2006.
Development of Model Systems to Assess the Role of Estrogens in Neuroprotection. American Aging
Association: Estrogen Neuroprotection: From Molecules to Humans, San Diego, CA June 10, 2002
Estrogen in the Brain: Role in Memory & Cognition. Assoc Women Sci, Phila Chapter, Radnor, PA, 2000
Women’s Health Care in the 90’s. Buck’s County Women Business Assoc, Quakertown, PA, 1996
Pharmacology of Cyclic Peptides in Drug Research, SIM, Boston, MA, 1994
Receptor pharmacology of anti-addictive drugs. Capital District Drug Abuse. Albany, NY, 1991
Receptor pharmacology of Ibogaine: a treatment for addiction. Capital District Drug Abuse, Albany, NY, 1990
PROFESSIONAL AWARDS
"Women of the Year" for Scientitic Contributions to Advancement of Women's Health. Presented at "Passion,
Purpose Pathways Luncheon. 5/22/08 Women's Resource Center, Union League, Philadelphia, PA (2008)
Wyeth Recognition award for valuable, individual contribution to the success of DVS [Pristiq] (2006)
Special Recognition Award for outstanding contribution to the operations of Wyeth Research (2000)
SUMMER INTERN/MENTORING PROGRAM
Ciana Hayes, Ursinus College- currently Medical School- Temple, Philadelphia, PA (2004)
Margo Montgomery, Villanova College- Completed Medical School Jefferson, Philadelphia, PA (2002-2003)
Kaya Jones, Completed Medical School (2003)
Adriene Shey, Completed Graduate School (2002)

10. Page 10 DARLENE C. DEECHER, Ph.D. 215-536-8789
Maria Seme Nelson, Northwestern University- currently employed by Wyeth, Chazy, NY (1996)
ADJUNCT TEACHING EXPERIENCE
Chicago Medical College, Pharmacology Dept. North Chicago, IL (Pharmacology, 1992-1994)
Mohawk Valley Community College, Biology Dept., Utica, NY (Biology, 1983-1988)
SUNY College of Technology, Biology Dept., Utica, NY (Human Genetics, 1986-1987)
ACTIVE PROFESSIONAL MEMBERSHIPS
Society of Neuroscience (1989-) and Endocrine Society (2005-)